Monte Rosa Therapeutics, Inc.
GLUEBiological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001826457
Revenue FY2025
$124.0M
Net Income
$(39.0M)
EPS (Basic)
—
Net Margin
-31.2%
ROE
-16.6%
Total Equity
$233.0M
Shares Out
85M
Monte Rosa Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 4 funds in our universe
Insider Transactions
Reading stored insider transactions…